Immunogenicity of neoantigens from hepatocellular carcinoma patients treated with a combined radioimmunotherapy - PubMed
5 hours ago
- #immunotherapy
- #hepatocellular carcinoma
- #neoantigens
- Study focuses on immunogenicity of neoantigens in hepatocellular carcinoma (HCC) patients treated with combined radioimmunotherapy.
- Neoantigen-specific immune responses were detected in 75% of patients with clinical benefit (B) and 83% of patients with no benefit (NB).
- In vivo experiments in HLA transgenic mice showed responses against most neoantigens (87% for HLA-A*02.01 and 73% for HLA-DRB1*01).
- Polyepitopic peptide vaccination induced stronger and broader T-cell responses compared to DNA vaccines.
- Results support the potential utility of neoantigens in therapeutic vaccines to enhance antitumor immunity.